Nov 15, 2009 0
The combination of the immunomodulatory drug lenalidomide and the proteasome inhibitor bortezomib appears to be both safe and potentially able to induce durable responses in patients with relapsed or relapsed/refractory multiple myeloma, U.S. researchers report online in the Journal of Clinical Oncology. Read the rest of this entry »
Oct 27, 2009 0
“This novel proteasome inhibitor appears to improve response rates and
survival in patients with progressive multiple myeloma.” Read the rest of this entry »
 |
Mackenzie Iarussi on Acupuncture Offers Relief to Breast Cancer Patients With Hot Flashes |
 |
hosting on cancer and sexuality (part 3) - what remedies are available for changes? |
 |
Dre Beats Headphons on novel agents and treatment of advanced NSLC |
 |
Antonello on No NHS Funding For Breast Cancer Drug Lapatinib |
 |
Incostress on cancer and sexuality (part 3) - what remedies are available for changes? |
Most Commented